摘要
目的探讨孟鲁司特钠联合黄芪注射液对支气管哮喘的临床疗效。方法将91例支气管哮喘患儿按随机数字表法分为观察组(n=46)和对照组(n=45)。观察组给予孟鲁司特钠咀嚼片联合黄芪注射液治疗,对照组给予酮替芬治疗。观察2组治疗前、治疗2周后肺功能指标[第1秒用力呼气容积(FEV1)、肺活量(VC)]、血清金属蛋白酶组织抑制剂-1(TIMP-1)、嗜酸性粒细胞趋化因子(Eotaxin)水平的变化及临床疗效。结果观察组总有效率为86.96%,明显高于对照组的66.67%(P<0.05)。与对照组比较,观察组治疗2周后VC、FEV1水平均明显升高,血清TIMP-1、Eotaxin水平均明显降低(均P<0.05)。结论孟鲁司特钠联合黄芪注射液治疗支气管哮喘具有较好的疗效,能够降低血清TIMP-1、Eotaxin水平,改善患儿的症状及肺功能。
Objective To explore the clinical effect of Montelukast Sodium combined with Astragalus membranaceus injection on bronchial Asthma.Methods Ninety-one children with bronchial asthma were randomly assigned to receive either Montelukast sodium chewable tablets combined with Astragalus membranaceus injection（observation group,n=46）or ketotifen（control group,n=45）.The forced expiratory volume in 1 second（FEV1）,vital capacity（VC）and serum levels of tissue inhibitor of metalloproteinases-1（TIMP-1）and Eotaxin were measured before and after treatment for 2 weeks.Results The total effective rate in observation group（86.96%）was higher than that in control group（66.67%）（P〈0.05）.In addition,compared with control group,the VC and FEV1 increased and serum TIMP-1 and Eotaxin levels decreased in observation group after treatment for 2 weeks（P〈0.05）.Conclusion Montelukast sodium combined with Astragalus membranaceus injection can effectively reduce serum TIMP-1 and eotaxin levels and improve symptoms and lung function in children with bronchial asthma.
作者
牛文静
NIU Wen-jing(The First Department of Pediatrics,Xinxiang Second People’s Hospital,Xinxiang 453000,Chin)
出处
《实用临床医学（江西）》
CAS
2018年第4期60-62,共3页
Practical Clinical Medicine
